Literature DB >> 17914441

Effect of semen sampling frequency on seminal antiretroviral drug concentration.

Y J Cao1, T T Ndovi, T L Parsons, A M Guidos, B Caffo, C W Hendrix.   

Abstract

Study of male genital tract (MGT) pharmacology is relevant to the treatment of prostatitis, prostate cancer, infertility, and seminal human immunodeficiency virus transmission. However, the time course of drug concentrations in the MGT is largely unknown. To determine the feasibility of frequent semen sampling in assessing the pharmacokinetics of the MGT, we administered efavirenz, indinavir, and zidovudine to subjects to achieve steady-state levels and then collected semen samples at sequentially decreasing ejaculation intervals. The volume of seminal plasma decreased from 4.0 (1.2-5.1) ml (median with range) at 48 h after the baseline ejaculation to 0.72 (0.45-1.6) ml 1 h after a previous ejaculation, which was still adequate for drug concentration assessment. The seminal fructose concentration also decreased. However, the concentration of prostate-specific antigen and all three drugs did not decrease, even if the ejaculation intervals decreased to 1 h. Thus, semi-intensive semen sampling can be used to assess MGT pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914441     DOI: 10.1038/sj.clpt.6100356

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  The male genital tract is not a pharmacological sanctuary from efavirenz.

Authors:  L B Avery; R P Bakshi; Y J Cao; C W Hendrix
Journal:  Clin Pharmacol Ther       Date:  2011-06-01       Impact factor: 6.875

2.  A highly sensitive ultra performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) technique for quantitation of protein free and bound efavirenz (EFV) in human seminal and blood plasma.

Authors:  Lindsay B Avery; Teresa L Parsons; David J Meyers; Walter C Hubbard
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-10-08       Impact factor: 3.205

3.  Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.

Authors:  Kevin C Brown; Kristine B Patterson; Steven H Jennings; Stephanie A Malone; Nicholas J Shaheen; Heather M Asher Prince; Melissa Spacek; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

4.  Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.

Authors:  L B Avery; N Sacktor; J C McArthur; C W Hendrix
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

5.  Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.

Authors:  Lindsay B Avery; Jennifer L VanAusdall; Craig W Hendrix; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2012-11-19       Impact factor: 3.922

6.  Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

Authors:  Kevin C Brown; Kristine B Patterson; Stephanie A Malone; Nicholas J Shaheen; Heather M Asher Prince; Julie B Dumond; Melissa B Spacek; Paris E Heidt; Myron S Cohen; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

7.  Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.

Authors:  Julie B Dumond; Y Sunila Reddy; Luigi Troiani; Jose F Rodriguez; Arlene S Bridges; Susan A Fiscus; Geoffrey J Yuen; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

Review 8.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.